hinata komine全集，hinata komine写真-靓姿雅av
主，吾为尊打造平台搜索，提供优质的服务只要您想到天海翼哪一部最好看，为尊搜胜源天海翼步兵，平台打造全球最闪耀最炫女优资料百科！
当前位置： &
& hinata komine写真
hinata komine全集
百科迅源：靓姿雅av&&更讯员：隆阅娱星&&更讯时日：日&&
hinata komine（こみね - 、日 - ）は、東京都出身の元AV女優[1]。
&[非表示]&
3.1 アダルトビデオ
5 関連項目
6 外部リンク
人物[編集]
初体験は16歳のときに友達の兄と行った。性感帯はクリトリス、好きな体位は正常位[1]、駅弁
略歴[編集]
2008年10月、クリスタル映像よりAVデビュー。
2009年3月、MOODYZよりセルデビュー。
作品[編集]
アダルトビデオ[編集]hinata komine
たわわな果実（10月24日、クリスタル映像）[1]
ぷるるんウェイトレス（11月21日、クリスタル映像）[1]
爆乳3P潮吹き凄い顔*（12月19日、クリスタル映像）[1]
爆乳家庭教師（1月30日、クリスタル映像）[1]
爆乳ソープへいらっしゃい（2月6日、クリスタル映像）[1]
初セルVIP（3月13日、MOODYZ）[2]
爆乳ヤリマン女教師（4月1日、MOODYZ）[2]
MOODYZ SEX SPECIAL（5月13日、MOODYZ）[2]
93cm Gcup（6月19日、OPPAI）
103cmJcup 93cmGcup 90cmGcup 85cmFcup OPPAIメイドのやりすぎご奉仕大乱*（7月19日、OPPAI）共演:NEIRO(鈴香音色)、CHISA(星島ちさ)、SATOMI（鈴木さとみ）
超爆乳ボディSPECIAL（8月13日、MOODYZ）共演:花井メイサ、青木りん、あのあるる[2]
真性中出し（9月1日、MOODYZ）[2]
*乳診断書04～触診シリーズ～（10月15日、グローリークエスト）
ボイン大好きしょう太くんのHなイタズラ～小峰ひなたの幼なじみのお姉さん編～（11月5日、グローリークエスト）
Gyu! 真正中出しラブリーデート（12月27日、モブスターズ）
初菊 ～小峰ひなたの初アナル中出し～（3月25日、Fantasista）
10人姉妹の真ん中に男は僕1人だけ! 大家族 岩田家の一週間 ～ボクのビッグダディ（チ○ポ）は休む暇なし! 貧乏だけどタマらん我が家～ 前編（4月6日、ディープス）共演:さくらい葉菜、水野美香、桃咲まなみ、安田美樹、みづなれい、桜木ハル、華原希、種村美咲、かわのすみれ
人妻中出し哀願 [其ノ十八]（4月23日、青空ソフト）
アナル浣腸150連発の惨劇 （4月25日、ダスッ!）
シェイクボディ Ver.14（5月7日、AVS collector&s）
10人姉妹の真ん中に男は僕1人だけ! 大家族 岩田家の一週間 ～まだまだ続く痛快オマ○コ性活! ボクのモーレツびんびん物語～ 後編（5月13日、ディープス）共演:さくらい葉菜、水野美香、桃咲まなみ、安田美樹、みづなれい、桜木ハル、華原希、種村美咲、かわのすみれ
アナル中出し20連発!（5月19日、イエロー）
VS.（5月25日、デジタルアーク）
タイトスカート尻コキ（6月1日、Fetishist/妄想族）共演:大沢美加、希内あんな、彩佳リリス、白砂ゆの、諸星セイラ、宮坂レイア、山口あずさ、茉莉花、紗奈、ふわり、水城奈緒、相原れな、他
手コキでベロちゅ～ 12 （6月19日、イエロー）出演:愛音ゆり、伊藤ユリエ、長谷川杏実、伊東麻央、泉麻那、星崎アンリ、梅宮リナ、森永ひよこ、さくら、柳田やよい、かわのすみれ
団地妻生中出し 17（7月9日、TMA）共演:紗奈、松すみれ、安藤美沙
快楽悩殺的痴女遊戯 第一章 おじさんをカワイく誘惑する、ムチムチロリの女子校生、ひなたちゃん（7月13日、AVS collector&s）
S級女子社員生中出し 02（7月16日、グレイズ）
Glam Mode（7月23日、デジタルアーク）
*乳若妻と*乳フェチな義弟の背徳（8月5日、ヒビノ）
限界調教3（10月1日、中嶋興業）
になるアノ娘& ～ひなた～（10月28日、WEEKENDER）
甘えん坊旅行 愛らしくてHなママとの温泉の旅（11月13日、アロマ企画）
ヌキヌキ＋CLINIC（12月3日、WEEKENDER）
「私、借金をアナルで返済いたします」 ドM*乳女子大生（1月6日、グローリークエスト）
めざましフェラチオ（1月20日、グローリークエスト）共演:浜崎りお、北条麻妃 翼裕香 横山みれい、森元あすか、皆澤奏美、澤村レイコ、花木あのん、仁科百華、中居ちはる、音和礼子、弘前亮子、森ななこ、竹内結、春咲あずみ、恵けい、榊なち、瀬奈涼、管野しずか
小峰ひなた初めての辱め散歩これが私の限界です! (2月5日、ATOM)
ご奉仕痴女3 ～わたし!!フェラ!!ごっくん!!H!!大好き～（2月25日、ハヤブサ）
露出デート 01（4月20日、プールクラブ・エンタテインメント）
着衣してても爆乳っぷりがスゴ過ぎる女 4（5月19日、グローリークエスト）
東京FUNKY GALS EX 07（6月24日、ピエロ）
尻伝説（7月18日、実録出版）
ご奉仕が大好きな*乳たち（7月22日、ハヤブサ）共演: 北川エリカ、百花エミリ、飯島和香、長谷川夢、秋本ゆいか、奥井レナ、来栖あさみ、大堀香奈、小坂めぐる、茉莉花、長澤あずさ、森永ひよこ、横山みれい、福山優、橘なお、平山薫、北川瞳
汗っかきなエロパイお姉さんはおっぱいがプルンプルン&（7月25日、デジタルアーク）
童貞筆おろし ママのおっぱいで卒業した～い（10月7日、クリスタル映像）
いけない全裸生活 ～男根一本に群がる*女たち～（10月25日、美）共演:成瀬心美、北川瞳
顔面騎乗 尻フェチ専科 5（10月31日、実録出版）
癒らしいむにゅむにゅボディーに痴女られたい（1月1日、Fetish Box/妄想族）
E-BODY（1月13日、E-BODY）
雪村春樹 艶縄集 5（2月13日、赤ほたるいか/妄想族）
*乳ママに赤ちゃん言葉で癒されたい（3月1日、Fetish Box/妄想族）
*乳ペニバンQUEEN 揺れるおっぱいとアナルFUCK（4月5日、未来）
射*するまで完全受身 **乳痴女にイカされたい（4月5日、ジャネス）
Hなひなたん（6月25日、日本コンテンツ流通）イメージビデオ
美麗顔騎妻（8月6日、メディア総販ソレイル）hinata komine
非道徳エロス小話集 若く豊満なカラダを持つ身寄りのない女たち（9月1日、FAプロ・プラチナ）共演:羽月希、平山薫、松見純
射*玩具 M男手*ザーメン狩り（9月5日、未来）共演:白咲舞、星崎アンリ、愛原つばさ、桐原あずさ、風見渚、有村千佳
ムチムチタイトスカートバス 2 万年発情期なのはパッツン生地でデカ尻が強調されるから!? 人目を気にせず挑発してくる肉感美人OL（9月6日、ディープス）共演:前田陽菜、春希ゆきの、杏子ゆう、大槻ひびき
外国人留学生が盗撮したホームステイ先の*乳母娘との肉体関係の全記録（11月1日、グローリークエスト）共演:加山なつこ
全力逃走レイプ（11月1日、グローリークエスト）共演:綾瀬れん、原望美、遥めぐみ、星川麻美
雪村春樹 縄情話 第五集（12月13日、赤ほたるいか/妄想族）共演:羽月希
女スパイ暴虐拷問室8（12月19日、シネマジック）
美しきSEX中毒な痴女たち（2月5日、ジャネス）共演:水嶋あずみ、泉麻那、北川みなみ、水沢真樹、榊なち、桐原あずさ
爆乳妻は2*中出しがお好き!（2月22日、Mellow Moon）
団地妻 旦那には言えない*らに疼く昼下がり（3月25日、ビッグモーカル）共演:眞木あずさ、ゆうきさやか
WEB[編集]hinata komine
デラ☆エロパラ（GyaOジョッキー、日ゲスト出演）
01. 02. 03. 04. 05. 06. 07. 08. 09. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50.
猜你会喜欢
01. 02. 03. 04. 05. 06. 07. 08.You are using an unsupported browser. Please upgrade your browser to
a newer version to get the best experience on
DrugBank. IdentificationNameGlyburideAccession NumberDB01016& (APRD00233) TypeSmall MoleculeGroupsApprovedDescriptionGlyburide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating & cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic & cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Glyburide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Glyburide appears to be completely metabolized, likely in the liver. Although its metabolites exert a small hypoglycemic effect, their contribution to glyburide’s hypoglycemic effect is thought to be clinically unimportant. Glyburide metabolites are excreted in urine and feces in approximately equal proportions. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m2.StructureSynonymsSynonymLanguageCode1-((P-(2-(5-chloro-O-Anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylureaNot AvailableNot Available1-(P-(2-(5-chloro-2-Methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylureaNot AvailableNot Available5-chloro-N-(2-(4-((((Cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamideNot AvailableNot AvailableDiabetaNot AvailableNot AvailableGlibenclamidaSpanishINNGlibenclamideNot AvailableINNGlibenclamidumLatinINNGlyburideNot AvailableNot AvailableGlynaseNot AvailableNot AvailableMicronaseNot AvailableNot AvailablePrescription ProductsNameDosageStrengthRouteLabellerMarketing StartMarketing EndGlynasetablet1.5 mgoralPharmacia and Upjohn CompanyNot AvailableUSGlynasetablet3 mgoralPharmacia and Upjohn CompanyNot AvailableUSGlynasetablet6 mgoralPharmacia and Upjohn CompanyNot AvailableUSDiabetatablet2.5 mgoralSanofi Aventis U.S. LlcNot AvailableUSDiabetatablet5 mgoralSanofi Aventis U.S. LlcNot AvailableUSDiabetatablet1.25 mgoralSanofi Aventis U.S. LlcNot AvailableUSGlyburidetablet5 mgoralTeva Pharmaceuticals USA IncNot AvailableUSGlyburidetablet2.5 mgoralTeva Pharmaceuticals USA IncNot AvailableUSGlyburidetablet1.25 mgoralTeva Pharmaceuticals USA IncNot AvailableUSGlyburidetablet5 mgoralPd Rx Pharmaceuticals, Inc.Not AvailableUSGlyburidetablet5 mgoralAphena Pharma Solutions
Tennessee, LlcNot AvailableUSGlyburidetablet2.5 mgoralAphena Pharma Solutions
Tennessee, LlcNot AvailableUSGlyburidetablet1.25 mgoralAphena Pharma Solutions
Tennessee, LlcNot AvailableUSGlyburidetablet2.5 mgoralPd Rx Pharmaceuticals, Inc.Not AvailableUSGlyburidetablet2.5 mgoralLegacy Pharmaceutical PackagingNot AvailableUSGlyburidetablet5 mgoralLegacy Pharmaceutical PackagingUSDiabetatablet2.5 mgoralSanofi Aventis Canada IncNot AvailableNot AvailableCanadaDiabetatablet5 mgoralSanofi Aventis Canada IncNot AvailableNot AvailableCanadaEuglucontablet5 mgoralPharmascience IncNot AvailableNot AvailableCanadaGeneric Prescription ProductsNameDosageStrengthRouteLabellerMarketing StartMarketing EndGlyburidetablet1.5 mgoralTeva Pharmaceuticals USA IncNot AvailableUSGlyburidetablet3 mgoralTeva Pharmaceuticals USA IncNot AvailableUSGlyburidetablet6 mgoralTeva Pharmaceuticals USA IncNot AvailableUSGlyburidetablet1.25 mgoralTeva Pharmaceuticals USA IncNot AvailableUSGlyburidetablet2.5 mgoralTeva Pharmaceuticals USA IncNot AvailableUSGlyburidetablet5 mgoralTeva Pharmaceuticals USA IncNot AvailableUSGlyburidetablet1.5 mgoralWest ward Pharmaceutical CorpNot AvailableUSGlyburidetablet3 mgoralWest ward Pharmaceutical CorpNot AvailableUSGlyburidetablet6 mgoralWest ward Pharmaceutical CorpNot AvailableUSGlyburidetablet1.5 mgoralMylan Pharmaceuticals Inc.Not AvailableUSGlyburidetablet3 mgoralMylan Pharmaceuticals Inc.Not AvailableUSGlyburidetablet6 mgoralMylan Pharmaceuticals Inc.Not AvailableUSGlyburidetablet5 mgoralNcs Health Care Of Ky, Inc Dba Vangard LabsNot AvailableUSGlyburidetablet2.5 mgoralNcs Health Care Of Ky, Inc Dba Vangard LabsNot AvailableUSGlyburidetablet1.25 mgoralMajor PharmaceuticalsNot AvailableUSGlyburidetablet2.5 mgoralMajor PharmaceuticalsNot AvailableUSGlyburidetablet5 mgoralMajor PharmaceuticalsNot AvailableUSGlyburidetablet2.5 mgoralRebel Distributors CorpNot AvailableUSGlyburidetablet5 mgoralRebel Distributors CorpNot AvailableUSGlyburidetablet1.25 mgoralHeritage Pharmaceuticals Inc.Not AvailableUSGlyburidetablet2.5 mgoralHeritage Pharmaceuticals Inc.Not AvailableUSGlyburidetablet5 mgoralHeritage Pharmaceuticals Inc.Not AvailableUSGlyburidetablet5 mgoralAidarex Pharmaceuticals LLCNot AvailableUSGlyburidetablet2.5 mgoralAidarex Pharmaceuticals LLCNot AvailableUSGlyburidetablet2.5 mgoralLake Erie Medical DBA Quality Care Products LLCNot AvailableUSGlyburidetablet1.25 mgoralLake Erie Medical DBA Quality Care Products LLCNot AvailableUSGlyburidetablet5 mgoralRebel Distributors CorpNot AvailableUSGlyburidetablet6 mgoralRebel Distributors CorpNot AvailableUSGlyburidetablet2.5 mgoralAv Kare, Inc.Not AvailableUSGlyburidetablet5 mgoralAv Kare, Inc.Not AvailableUSGlyburidetablet3 mgoralPd Rx Pharmaceuticals, Inc.Not AvailableUSGlyburidetablet6 mgoralPd Rx Pharmaceuticals, Inc.Not AvailableUSGlyburidetablet5 mgoralREMEDYREPACK INC.Not AvailableUSGlyburidetablet2.5 mgoralREMEDYREPACK INC.Not AvailableUSGlyburidetablet2.5 mgoralREMEDYREPACK INC.Not AvailableUSGlyburidetablet2.5 mgoralREMEDYREPACK INC.Not AvailableUSGlyburidetablet5 mgoralLake Erie Medical DBA Quality Care Products LLCNot AvailableUSGlyburidetablet2.5 mgoralUnit Dose ServicesNot AvailableUSGlyburidetablet5 mgoralUnit Dose ServicesNot AvailableUSGlyburidetablet2.5 mgoralMylan Institutional Inc.Not AvailableUSGlyburidetablet5 mgoralMylan Institutional Inc.Not AvailableUSGlyburidetablet5 mgoralREMEDYREPACK INC.Not AvailableUSGlyburidetablet2.5 mgoralREMEDYREPACK INC.Not AvailableUSGlyburidetablet5 mgoralPhysicians Total Care, Inc.Not AvailableUSGlyburidetablet2.5 mgoralPhysicians Total Care, Inc.Not AvailableUSGlyburidetablet1.25 mgoralPhysicians Total Care, Inc.Not AvailableUSGlyburidetablet3 mgoralPhysicians Total Care, Inc.Not AvailableUSGlyburidetablet6 mgoralPhysicians Total Care, Inc.Not AvailableUSGlyburidetablet1.5 mgoralPhysicians Total Care, Inc.Not AvailableUSGlyburidetablet5 mgoralCardinal HealthNot AvailableUSGlyburidetablet5 mgoralCardinal HealthNot AvailableUSGlyburidetablet5 mgoralPd Rx Pharmaceuticals, Inc.Not AvailableUSGlyburidetablet1.25 mgoralCitron Pharma LLCNot AvailableUSGlyburidetablet2.5 mgoralCitron Pharma LLCNot AvailableUSGlyburidetablet5 mgoralCitron Pharma LLCNot AvailableUSGlyburidetablet2.5 mgoralClinical Solutions WholesaleNot AvailableUSGlyburidetablet5 mgoralClinical Solutions WholesaleNot AvailableUSGlyburidetablet6 mgoralHikma PharmaceuticalNot AvailableUSGlyburidetablet3 mgoralHikma PharmaceuticalNot AvailableUSGlyburidetablet1.5 mgoralHikma PharmaceuticalNot AvailableUSGlyburidetablet5 mgoralbryant ranch prepackNot AvailableUSGlyburidetablet2.5 mgoralbryant ranch prepackNot AvailableUSGlyburidetablet5 mgoralMc Kesson Packaging Services A Business Unit Of Mc Kesson CorporationNot AvailableUSGlyburidetablet2.5 mgoralCore Pharma, LlcNot AvailableUSGlyburidetablet5 mgoralCore Pharma, LlcNot AvailableUSGlyburidetablet5 mgoralTYA PharmaceuticalsNot AvailableUSGlyburidetablet1.25 mgoralAurobindo Pharma LimitedNot AvailableUSGlyburidetablet2.5 mgoralAurobindo Pharma LimitedNot AvailableUSGlyburidetablet5 mgoralAurobindo Pharma LimitedNot AvailableUSGlyburidetablet5 mgoralMed Vantx, Inc.Not AvailableUSGlyburidetablet2.5 mgoralDispensing Solutions, Inc.Not AvailableUSGlyburidetablet6 mgoralDispensing Solutions, Inc.Not AvailableUSGlyburidetablet5 mgoralContract Pharmacy Services PaNot AvailableUSGlyburidetablet1.5 mgoralDAVA Pharmaceuticals, Inc.Not AvailableUSGlyburidetablet3 mgoralDAVA Pharmaceuticals, Inc.Not AvailableUSGlyburidetablet6 mgoralDAVA Pharmaceuticals, Inc.Not AvailableUSGlyburidetablet5 mgoralAmerican Health PackagingNot AvailableUSGlyburidetablet5 mgoralPreferred Pharmaceuticals, Inc.Not AvailableUSGlyburidetablet5 mgoralMc Kesson Contract PackagingNot AvailableUSGlyburidetablet2.5 mgoralSanis Health IncNot AvailableNot AvailableCanadaGlyburidetablet5 mgoralSanis Health IncNot AvailableNot AvailableCanadaOver the Counter ProductsNot AvailableInternational BrandsNameCompanyDaonilNot AvailableDelmideNot AvailableMicronaseNot AvailableNovo-GlyburideNovopharmSemi-DaonilNot AvailableBrand mixturesBrand NameIngredientsBenimetMetformin + GlibenclamideGlibometMetformin + GlibenclamideGlucovanceMetformin + GlibenclamideSaltsNot AvailableCategories
CAS numberWeightAverage: 494.004 Monoisotopic: 493. Chemical FormulaC23H28ClN3O5SInChI KeyZNNLBTZKUZBEKO-UHFFFAOYSA-NInChIInChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)IUPAC Name5-chloro-N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-2-methoxybenzamideSMILESCOC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1TaxonomyDescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.KingdomSuper ClassClassSub ClassDirect ParentAlternative Parents
Substituents3-halobenzoic acid or derivatives
Salicylamide
Benzenesulfonamide
Phenethylamine
Benzoic acid or derivatives
Methoxybenzene
Phenol ether
Sulfonylurea
Halobenzene
Cyclohexylamine
Chlorobenzene
Alkyl aryl ether
Aryl halide
Aryl chloride
Aminosulfonyl compound
Sulfonic acid derivative
Sulfonamide
Secondary carboxylic acid amide
Carboxamide group
Carboxylic acid derivative
Hydrocarbon derivative
Organosulfur compound
Organooxygen compound
Organonitrogen compound
Organochloride
Organohalogen compound
Carbonyl group
Aromatic homomonocyclic compoundMolecular FrameworkAromatic homomonocyclic compoundsExternal Descriptorsorganochlorine compound ()N-sulfonylurea ()PharmacologyIndicationIndicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone.PharmacodynamicsGlyburide, a second-generation sulfonylurea antidiabetic agent, lowers blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glibenclamide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Glyburide is twice as potent as the related second-generation agent glipizide.Mechanism of actionSulfonylureas such as glyburide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.AbsorptionSignificant absorption within 1 hour and peak plasma levels are reached in 2 to 4 hours. Onset of action occurs within one hour. Volume of distributionSteady state Vd=0.125 L/ Vd during elimination phase=0.155 L/kg.Protein bindingUnchanged drug is ~99% bou 4-trans-hydroxyglyburide is greater than 97% bound to serum proteins. Protein binding is primarily nonionic making glyburide and is less likely to displace or be displaced by drugs that bind via an ionic mechanism. MetabolismPrimarily hepatic (mainly cytochrome P450 3A4). The major metabolite is the 4-trans-hydroxy derivative. A second metabolite, the 3-cis-hydroxy derivative, also occurs. These metabolites do not contribute clinically significant hypoglycemic action in humans as they ar however, retention of 4-trans-hydroxyglyburide may prolong the hypoglycemic effect of the agent in those with severe renal impairment. SubstrateEnzymesProductGlyburide
Route of eliminationGlyburide is excreted as metabolites in the bile and urine, approximately 50% by each route.
This dual excretory pathway is qualitatively different from that of other sulfonylureas, which are excreted primarily in the urine.Half life1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. Clearance78 ml/hr/kg in healthy adults. Clearance may be substantially decreased in those with severe renal impairment.ToxicityOral rat LD50: > 20,000 mg/kg. Oral mouse LD50: 3250 mg/kg.Affected organismsHumans and other mammalsPathwaysNot AvailableSNP Mediated EffectsNot AvailableSNP Mediated Adverse Drug ReactionsNot AvailableADMETPredicted ADMET featuresPropertyValueProbabilityHuman Intestinal Absorption+0.9701Blood Brain Barrier-0.6707Caco-2 permeable-0.6479P-glycoprotein substrateNon-substrate0.5109P-glycoprotein inhibitor INon-inhibitor0.7119P-glycoprotein inhibitor IINon-inhibitor0.8185Renal organic cation transporterNon-inhibitor0.7982CYP450 2C9 substrateSubstrate0.6488CYP450 2D6 substrateNon-substrate0.9116CYP450 3A4 substrateSubstrate0.5329CYP450 1A2 substrateNon-inhibitor0.9045CYP450 2C9 substrateInhibitor0.8948CYP450 2D6 substrateInhibitor0.8932CYP450 2C19 substrateNon-inhibitor0.9026CYP450 3A4 substrateInhibitor0.7959CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8627Ames testNon AMES toxic0.6996CarcinogenicityNon-carcinogens0.7539BiodegradationNot ready biodegradable0.8245Rat acute toxicity1.4243 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.7551hERG inhibition (predictor II)Non-inhibitor0.8024PharmacoeconomicsManufacturersSanofi aventis us llc
Actavis totowa llc
Aurobindo pharma ltd
Corepharma llc
Teva pharmaceuticals usa inc
Dava pharmaceuticals inc
Hikma pharmaceuticals
Mylan pharmaceuticals inc
Sandoz inc
Pharmacia and upjohn coPackagersAdvanced Pharmaceutical Services Inc.
Apotheca Inc.
Coupler Enterprises Inc.
DHHS Program Support Center Supply Service Center
Direct Dispensing Inc.
Heartland Repack Services LLC
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Liberty Pharmaceuticals
Merrell Pharmaceuticals Inc.
Novopharm Ltd.
Pharmaceutical Utilization Management Program VA Inc.
Prepackage Specialists
Resource Optimization and Innovation LLC
Talbert Medical Management Corp.
Va Cmop Dallas
Vangard Labs Inc.
Warrick Pharmaceuticals Corp.
Zoetica Pharmaceutical Corp.Dosage formsFormRouteStrengthTabletoral1.25 mgTabletoral1.5 mgTabletoral2.5 mgTabletoral3 mgTabletoral5 mgTabletoral6 mgPricesUnit descriptionCostUnitGlynase 6 mg tablet2.28USD tabletGlynase 6 mg prestab2.19USD tabletGlynase 3 mg tablet1.45USD tabletGlynase 3 mg prestab1.39USD tabletDiabeta 5 mg tablet1.36USD tabletMicronase 5 mg tablet1.36USD tabletDiabeta 2.5 mg tablet0.91USD tabletGlynase 1.5 mg tablet0.83USD tabletGlynase 1.5 mg prestab0.82USD tabletMicronase 2.5 mg tablet0.8USD tabletDiabeta 1.25 mg tablet0.5USD tabletMicronase 1.25 mg tablet0.48USD tabletDiabeta 5 mg Tablet0.26USD tabletDiabeta 2.5 mg Tablet0.14USD tabletApo-Glyburide 5 mg Tablet0.07USD tabletEuglucon 5 mg Tablet0.07USD tabletMylan-Glybe 5 mg Tablet0.07USD tabletNovo-Glyburide 5 mg Tablet0.07USD tabletNu-Glyburide 5 mg Tablet0.07USD tabletPms-Glyburide 5 mg Tablet0.07USD tabletRatio-Glyburide 5 mg Tablet0.07USD tabletSandoz
Glyburide 5 mg Tablet0.07USD tabletApo-Glyburide 2.5 mg Tablet0.04USD tabletEuglucon 2.5 mg Tablet0.04USD tabletMylan-Glybe 2.5 mg Tablet0.04USD tabletNovo-Glyburide 2.5 mg Tablet0.04USD tabletNu-Glyburide 2.5 mg Tablet0.04USD tabletPms-Glyburide 2.5 mg Tablet0.04USD tabletRatio-Glyburide 2.5 mg Tablet0.04USD tabletSandoz Glyburide 2.5 mg Tablet0.04USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only. PatentsNot AvailablePropertiesStateSolidExperimental PropertiesSourcemelting point169 °CPhysPropwater solubility4 mg/L (at 27 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)logP4.7Not AvailablelogS-5.09ADME Research, USCDPredicted PropertiesSourceWater Solubility0.00206 mg/mLlogP3.78logP3.79logS-5.4pKa (Strongest Acidic)4.32pKa (Strongest Basic)-1.2Physiological Charge-1Hydrogen Acceptor Count5Hydrogen Donor Count3Polar Surface Area113.6 ?2Rotatable Bond Count7Refractivity126.98 m3·mol-1Polarizability51.75 ?3Number of Rings3Bioavailability1Rule of FiveYesGhose FilterYesVeber's RuleYesMDDR-like RuleYesSpectraMass Spec (NIST)Not AvailableSpectraNot AvailableReferencesSynthesis ReferenceSuresh Gidwani, “Solid oral dosage form of metformin and glyburide and the method of preparation thereof.” U.S. Patent US, issued September 09, 2004.General Reference
Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, Masotti G, Marchionni N, Mannucci E: Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006 Nov-D22(6):477-82.
External LinksResourceLinkKEGG DrugKEGG CompoundPubChem CompoundPubChem SubstanceChemSpiderChEBIChEMBLTherapeutic Targets DatabasePharmGKBIUPHARGuide to PharmacologyRxListWikipediaATC CodesA10BB01AHFS Codes68:20.20PDB EntriesNot AvailableFDA labelNot AvailableMSDS (36.9 KB) InteractionsDrug InteractionsAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hepatotoxic effect of Bosentan. Bosentan may increase the metabolism of GlyBURIDE. GlyBURIDE may increase the metabolism of Bosentan.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of other Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May decrease the metabolism of Sulfonylureas.Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.May increase the serum concentration of Sulfonylureas.May increase the serum concentration of GlyBURIDE.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Colesevelam may decrease the serum concentration of GlyBURIDE.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May decrease the serum concentration of CYP2C9 Substrates.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.May enhance the hypoglycemic effect of Hypoglycemic Agents.CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of other Hypoglycemic Agents.May increase the serum concentration of Sulfonylureas.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of other Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of other Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of other Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Sulfonylureas.May enhance the hypoglycemic effect of Hypoglycemic Agents.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of other Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of other Hypoglycemic Agents.CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.May enhance the hypoglycemic effect of other Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May increase the serum concentration of Sulfonylureas.May enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of other Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.May enhance the hypoglycemic effect of Hypoglycemic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.May enhance the hypoglycemic effect of Hypoglycemic Agents.May increase the serum concentration of Sulfonylureas.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.Food InteractionsAvoid alcohol.
Take 30-60 minutes before breakfast.Targets
Kind: protein
Organism: Human
Pharmacological action:
Components
ATP-binding cassette sub-family C member 8
References:
Dabrowski M, Ashcroft FM, Ashfield R, Lebrun P, Pirotte B, Egebjerg J, Bondo Hansen J, Wahl P: The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener. Diabetes. ):.
Hambrock A, Preisig-Muller R, Russ U, Piehl A, Hanley PJ, Ray J, Daut J, Quast U, Derst C: Four novel splice variants of sulfonylurea receptor 1. Am J Physiol Cell Physiol. ):C587-98.
Hambrock A, Loffler-Walz C, Quast U: Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides. Br J Pharmacol. ):995-1004.
Nielsen FE, Bodvarsdottir TB, Worsaae A, MacKay P, Stidsen CE, Boonen HC, Pridal L, Arkhammar PO, Wahl P, Ynddal L, Junager F, Dragsted N, Tagmose TM, Mogensen JP, Koch A, Treppendahl SP, Hansen JB: 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells. J Med Chem. 2002 Sep 12;45(19):4171-87.
Babenko AP, Bryan J: SUR-dependent modulation of KATP channels by an N-terminal KIR6.2 peptide. Defining intersubunit gating interactions. J Biol Chem. 2002 Nov 15;277(46):. Epub 2002 Sep 3.
Ueda K, Komine J, Matsuo M, Seino S, Amachi T: Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1268-72.
Serrano-Martin X, Payares G, Mendoza-Leon A: Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrob Agents Chemother. ):4214-6. Epub 2006 Oct 2.
Hambrock A, Loffler-Walz C, Quast U: Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides. Br J Pharmacol. ):995-1004.
Kind: protein
Organism: Human
Pharmacological action:
Components
ATP-sensitive inward rectifier potassium channel 1
References:
Pondugula SR, Raveendran NN, Ergonul Z, Deng Y, Chen J, Sanneman JD, Palmer LG, Marcus DC: Glucocorticoid regulation of genes in the amiloride-sensitive sodium transport pathway by semicircular canal duct epithelium of neonatal rat. Physiol Genomics. 2006 Jan 12;24(2):114-23. Epub 2005 Nov 1.
Lu M, Leng Q, Egan ME, Caplan MJ, Boulpaep EL, Giebisch GH, Hebert SC: CFTR is required for PKA-regulated ATP sensitivity of Kir1.1 potassium channels in mouse kidney. J Clin Invest. ):797-807. Epub 2006 Feb 9.
Kind: protein
Organism: Human
Pharmacological action:
Components
G protein-activated inward rectifier potassium channel 4
References:
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
Kind: protein
Organism: Human
Pharmacological action:
Components
ATP-binding cassette sub-family C member 9
References:
Hambrock A, Loffler-Walz C, Quast U: Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides. Br J Pharmacol. ):995-1004.
Rainbow RD, James M, Hudman D, Al Johi M, Singh H, Watson PJ, Ashmole I, Davies NW, Lodwick D, Norman RI: Proximal C-terminal domain of sulphonylurea receptor 2A interacts with pore-forming Kir6 subunits in KATP channels. Biochem J. 2004 Apr 1;379(Pt 1):173-81.
Felsch H, Lange U, Hambrock A, Loffler-Walz C, Russ U, Carroll WA, Gopalakrishnan M, Quast U: Interaction of a novel dihydropyridine K+ channel opener, A-312110, with recombinant sulphonylurea receptors and KATP channels: comparison with the cyanoguanidine P1075. Br J Pharmacol. ):. Epub 2004 Mar 15.
Zhao JL, Yang YJ, You SJ, Jing ZC, Wu YJ, Cheng JL, Gao RL: Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coron Artery Dis. ):463-9.
Wang YH, Zheng HY, Qin NL, Yu SB, Liu SY: Involvement of ATP-sensitive potassium channels in proliferation and differentiation of rat preadipocytes. Sheng Li Xue Bao. 2007 Feb 25;59(1):8-12.
Hambrock A, Loffler-Walz C, Quast U: Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides. Br J Pharmacol. ):995-1004.
Kind: protein
Organism: Human
Pharmacological action:
Components
Bile salt export pump
References:
Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. ):1649-58.
Kemp DC, Brouwer KL: Viability assessment in sandwich-cultured rat hepatocytes after xenobiotic exposure. Toxicol In Vitro. ):869-77.
Horikawa M, Kato Y, Tyson CA, Sugiyama Y: Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet. ):16-22.
Kind: protein
Organism: Human
Pharmacological action:
Components
ATP-binding cassette sub-family A member 1
References:
Reddy ST, Hama S, Ng C, Grijalva V, Navab M, Fogelman AM: ATP-binding cassette transporter 1 participates in LDL oxidation by artery wall cells. Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1877-83.
Muhl H, Hofler S, Pfeilschifter J: Inhibition of lipopolysaccharide/ATP-induced release of interleukin-18 by KN-62 and glyburide. Eur J Pharmacol. 2003 Dec 15;482(1-3):325-8.
Agassandian M, Mathur SN, Zhou J, Field FJ, Mallampalli RK: Oxysterols trigger ABCA1-mediated basolateral surfactant efflux. Am J Respir Cell Mol Biol. ):227-33. Epub 2004 Mar 23.
Nieland TJ, Chroni A, Fitzgerald ML, Maliga Z, Zannis VI, Kirchhausen T, Krieger M: Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide. J Lipid Res. ):1256-65. Epub 2004 Apr 21.
Alder-Baerens N, Muller P, Pohl A, Korte T, Hamon Y, Chimini G, Pomorski T, Herrmann A: Headgroup-specific exposure of phospholipids in ABCA1-expressing cells. J Biol Chem. 2005 Jul 15;280(28):26321-9. Epub 2005 May 19.
Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM: Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009 Oct 5;187(1):61-70. doi: 10.1083/jcb..
Kind: protein
Organism: Human
Pharmacological action:
antagonist
Components
Cystic fibrosis transmembrane conductance regulator
References:
Reddy MM, Quinton PM: Effect of anion transport blockers on CFTR in the human sweat duct. J Membr Biol. 2002 Sep 1;189(1):15-25.
Jiang J, Song Y, Bai C, Koller BH, Matthay MA, Verkman AS: Pleural surface fluorescence measurement of Na+ and Cl- transport across the air space-capillary barrier. J Appl Physiol. ):343-52. Epub 2002 Aug 30.
Zhou Z, Hu S, Hwang TC: Probing an open CFTR pore with organic anion blockers. J Gen Physiol. ):647-62.
Larsen EH, Amstrup J, Willumsen NJ: Beta-adrenergic receptors couple to CFTR chloride channels of intercalated mitochondria-rich cells in the heterocellular toad skin epithelium. Biochim Biophys Acta. 2003 Dec 30;0-52.
Lee SY, Lee CO: Inhibition of Na+-K+ pump and L-type Ca2+ channel by glibenclamide in Guinea pig ventricular myocytes. J Pharmacol Exp Ther. ):61-8. Epub 2004 Sep 13.
Kind: protein
Organism: Human
Pharmacological action:
Components
ATP-sensitive inward rectifier potassium channel 11
References:
Hambrock A, Loffler-Walz C, Quast U: Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides. Br J Pharmacol. ):995-1004.
Nielsen FE, Bodvarsdottir TB, Worsaae A, MacKay P, Stidsen CE, Boonen HC, Pridal L, Arkhammar PO, Wahl P, Ynddal L, Junager F, Dragsted N, Tagmose TM, Mogensen JP, Koch A, Treppendahl SP, Hansen JB: 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells. J Med Chem. 2002 Sep 12;45(19):4171-87.
Gojkovic-Bukarica L, Hambrock A, Loffler-Walz C, Quast U, Russ U: Mg2+ sensitizes KATP channels to inhibition by DIDS: dependence on the sulphonylurea receptor subunit. Br J Pharmacol. ):429-40.
Ball AJ, McCluskey JT, Flatt PR, McClenaghan NH: Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K(ATP) channel components. Pharmacol Res. ):41-6.
Lim JG, Lee HY, Yun JE, Kim SP, Park JW, Suh SI, Jang BC, Cho CH, Bae JH, Kim SS, Han J, Park MJ, Song DK: Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes. Biochem Pharmacol. 2004 Sep 1;68(5):901-10.
Kind: protein group
Organism: Human
Pharmacological action:
Components
ATP-sensitive inward rectifier potassium channel 11
ATP-sensitive inward rectifier potassium channel 8
References:
Jaburek M, Yarov-Yarovoy V, Paucek P, Garlid KD: State-dependent inhibition of the mitochondrial KATP channel by glyburide and 5-hydroxydecanoate. J Biol Chem. 1998 May 29;273(22):13578-82.
Kind: protein
Organism: Human
Pharmacological action:
Components
Carnitine O-palmitoyltransferase 1, liver isoform
References:
Patel TB: Effect of sulfonylureas on hepatic fatty acid oxidation. Am J Physiol.
Pt 1):E241-6.
Cook GA: The hypoglycemic sulfonylureas glyburide and tolbutamide inhibit fatty acid oxidation by inhibiting carnitine palmitoyltransferase. J Biol Chem. 1987 Apr 15;262(11):4968-72.
Kind: protein
Organism: Human
Pharmacological action:
Components
Cytochrome P450 2C9
References:
Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. ):. Epub 2009 Sep 1.
Flockhart DA. . Indiana University School of Medicine (2007). Accessed May 28, 2010.
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 J38(Database issue):D237-43. Epub 2009 Nov 24.
Kind: protein
Organism: Human
Pharmacological action:
Components
Cytochrome P450 3A4
References:
Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. ):. Epub 2009 Sep 1.
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 J38(Database issue):D237-43. Epub 2009 Nov 24.
Kind: protein
Organism: Human
Pharmacological action:
Components
Cytochrome P450 2C19
References:
Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. ):. Epub 2009 Sep 1.
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 J38(Database issue):D237-43. Epub 2009 Nov 24.
Kind: protein
Organism: Human
Pharmacological action:
Components
Serum albumin
References:
Crooks MJ, Brown KF: The binding of sulphonylureas to serum albumin. J Pharm Pharmacol. ):304-11.
Hsu PL, Ma JK, Luzzi LA: Interactions of sulfonylureas with plasma proteins. J Pharm Sci. ):570-3.
Brown KF, Crooks MJ: Displacement of tolbutamide, glibencalmide and chlorpropamide from serum albumin by anionic drugs. Biochem Pharmacol. 1976 May 15;25(10):1175-8.
Transporters
Kind: protein
Organism: Human
Pharmacological action:
Components
Canalicular multispecific organic anion transporter 2
References:
Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-D27(11-12):. Epub 2006 Feb 3.
Kind: protein
Organism: Human
Pharmacological action:
Components
Bile salt export pump
References:
Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. ):1649-58.
Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. ):537-44.
Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. ):1223-31.
Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R: Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology. 2001 Oct 5;167(1):83-98.
Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. ):422-30.
Kind: protein
Organism: Human
Pharmacological action:
Components
Multidrug resistance protein 1
References:
Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. ):652-60.
Kind: protein
Organism: Human
Pharmacological action:
Components
Multidrug resistance-associated protein 1
References:
Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol. ):778-84.
Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-D27(11-12):. Epub 2006 Feb 3.
Kind: protein
Organism: Human
Pharmacological action:
Components
Solute carrier family 15 member 1
References:
Sawada K, Terada T, Saito H, Hashimoto Y, Inui K: Effects of glibenclamide on glycylsarcosine transport by the rat peptide transporters PEPT1 and PEPT2. Br J Pharmacol. ):1159-64.
Kind: protein
Organism: Human
Pharmacological action:
Components
Solute carrier organic anion transporter family member 1A2
References:
Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. ):147-53.
Kind: protein
Organism: Human
Pharmacological action:
Components
Solute carrier family 15 member 2
References:
Sawada K, Terada T, Saito H, Hashimoto Y, Inui K: Effects of glibenclamide on glycylsarcosine transport by the rat peptide transporters PEPT1 and PEPT2. Br J Pharmacol. ):1159-64.
Kind: protein
Organism: Human
Pharmacological action:
Components
Solute carrier family 22 member 6
References:
Uwai Y, Saito H, Hashimoto Y, Inui K: Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. Eur J Pharmacol. 2000 Jun 16;398(2):193-7.
Kind: protein
Organism: Human
Pharmacological action:
Components
Canalicular multispecific organic anion transporter 1
References:
Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-D27(11-12):. Epub 2006 Feb 3.
Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol. ):778-84.
Kind: protein
Organism: Human
Pharmacological action:
Components
ATP-binding cassette sub-family G member 2
References:
Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-D27(11-12):. Epub 2006 Feb 3.
Pollex EK, Anger G, Hutson J, Koren G, Piquette-Miller M: Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos. ):740-4. Epub 2010 Feb 16.
Kind: protein
Organism: Human
Pharmacological action:
Components
Solute carrier family 22 member 7
References:
Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. ):1179-84.
Kind: protein
Organism: Human
Pharmacological action:
Components
Solute carrier organic anion transporter family member 2B1
References:
Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. ):518-23. Epub 2005 Jan 7.
Please enable JavaScript to view the
Drug created on June 13,
/ Updated on September 16, This project is supported by the
(award #111062), , and by , a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by , , and , a not-for-profit organization that is leading Canada's national genomics strategy with $900 million in funding from the federal government.DrugBank Version